Study of Ruxolitinib in Colorectal Cancer Patients
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib,
is safe and effective in the treatment of metastatic colorectal cancer.